Cerus Corporation Total Assets 2011-2026 | CERS

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Cerus Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
201 M	198 M	218 M	237 M	221 M	166 M	163 M	98.2 M	103 M	139 M	81.8 M	83.4 M	48.9 M	45.4 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
237 M	45.4 M	143 M

Quarterly Total Assets Cerus Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
215 M	213 M	207 M	190 M	185 M	189 M	206 M	199 M	209 M	218 M	215 M	-	222 M	237 M	219 M	223 M	221 M	221 M	221 M	221 M	221 M	166 M	166 M	166 M	166 M	163 M	163 M	163 M	163 M	98.2 M	98.2 M	98.2 M	98.2 M	103 M	103 M	103 M	103 M	139 M	139 M	139 M	139 M	81.8 M	81.8 M	81.8 M	81.8 M	83.4 M	83.4 M	83.4 M	83.4 M	48.9 M	48.9 M	48.9 M	48.9 M	45.4 M	45.4 M	45.4 M	45.4 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
237 M	45.4 M	142 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Alector ALEC	293 M	$ 2.19	-9.77 %	$ 226 M	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Cabaletta Bio CABA	254 M	$ 3.34	0.45 %	$ 3.9 M	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Codexis CDXS	149 M	$ 1.02	1.49 %	$ 74.9 M	USA
AbCellera Biologics ABCL	1.36 B	$ 3.74	3.6 %	$ 1.12 B	Canada
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
Cellectis S.A. CLLS	384 M	$ 3.87	-0.39 %	$ 116 M	France
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
CNS Pharmaceuticals CNSP	8.7 M	$ 3.23	2.22 %	$ 1.23 M	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA
Collegium Pharmaceutical COLL	1.66 B	$ 41.75	0.19 %	$ 1.32 B	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Corcept Therapeutics Incorporated CORT	837 M	$ 36.14	1.23 %	$ 3.75 B	USA
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Amarin Corporation plc AMRN	832 M	$ 13.98	1.27 %	$ 5.7 B	Irlanda
Aileron Therapeutics ALRN	62.2 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	119 M	-	4.14 %	$ 49.1 M	USA
Catalyst Pharmaceuticals CPRX	1.1 B	$ 23.77	2.99 %	$ 2.91 B	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Corbus Pharmaceuticals Holdings CRBP	28.3 M	$ 8.41	-1.87 %	$ 36.4 M	USA
Cardiff Oncology CRDF	61.9 M	$ 1.94	0.01 %	$ 130 M	USA
Curis CRIS	41.3 M	$ 1.1	-3.51 %	$ 6.94 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
CorMedix CRMD	82.1 M	$ 7.16	0.42 %	$ 364 M	USA
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Champions Oncology CSBR	32.3 M	$ 6.14	3.89 %	$ 83.9 M	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Aptose Biosciences APTO	10.1 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Citius Pharmaceuticals CTXR	117 M	$ 0.72	-2.34 %	$ 4.84 M	USA
Athira Pharma ATHA	58.8 M	-	-	$ 269 M	USA
Aridis Pharmaceuticals ARDS	14.7 M	-	17.91 %	$ 11.1 M	USA
Altimmune ALT	139 M	$ 4.21	-2.32 %	$ 299 M	USA
CEL-SCI Corporation CVM	27 M	$ 3.88	-8.92 %	$ 247 M	USA